Terms: = Ovarian cancer AND YWHAE, P62258, 7531, ENSG00000108953, 14-3-3 epsilon, FLJ45465, MDS, MDCR, KCIP-1, 14-3-3E AND Treatment
24 results:
1. HAX1-related congenital neutropenia: Long-term observation in paediatric and adult patients enrolled in the European branch of the Severe Chronic Neutropenia International Registry (SCNIR).
Pogozhykh D; Yilmaz Karapinar D; Klimiankou M; Gerschmann N; Ebetsberger-Dachs G; Palmblad J; Carlsson G; Masmas T; Kinsey S; Bartels M; Mellor-Heineke S; Welte K; Skokowa J; Zeidler C
Br J Haematol; 2023 Jul; 202(2):393-411. PubMed ID: 37193639
[TBL] [Abstract] [Full Text] [Related]
2. Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous ovarian cancer (MOLTO): A Phase II Trial.
Morgan RD; Clamp AR; White DJ; Price M; Burghel GJ; Ryder WDJ; Mahmood RD; Murphy AD; Hasan J; Mitchell CL; Salih Z; Wheeler C; Buckley E; Truelove J; King G; Ainaoui Y; Bhaskar SS; Shaw J; Evans DGR; Kilerci B; Pearce SP; Brady G; Dive C; O'Connor JPB; Wallace AJ; Rothwell DG; Edmondson RJ; Jayson GC
Clin Cancer Res; 2023 Jul; 29(14):2602-2611. PubMed ID: 36799931
[TBL] [Abstract] [Full Text] [Related]
3. Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society.
Milani A; Tuninetti V; Pignata S; Lorusso D; Castaldo D; De Giorgi U; Savarese A; Biglia N; Scandurra G; Mangili G; Di Maio M; Turinetto M; Bellero M; Mammoliti S; Testa S; Scotto G; Purro A; Artioli G; Valabrega G
Tumori; 2023 Oct; 109(5):490-495. PubMed ID: 36609207
[TBL] [Abstract] [Full Text] [Related]
4. Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes.
Todisco E; Gigli F; Ronchini C; Amato V; Sammassimo S; Pastano R; Parma G; Lapresa MT; Bertolini F; Corsini C; Gregato G; Poletti C; Pelicci PG; Alcalay M; Colombo N; Tarella C
Int J Cancer; 2022 Nov; 151(10):1791-1803. PubMed ID: 35695283
[TBL] [Abstract] [Full Text] [Related]
5. Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment.
Morra A; Escala-Garcia M; Beesley J; Keeman R; Canisius S; Ahearn TU; Andrulis IL; Anton-Culver H; Arndt V; Auer PL; Augustinsson A; Beane Freeman LE; Becher H; Beckmann MW; Behrens S; Bojesen SE; Bolla MK; Brenner H; Brüning T; Buys SS; Caan B; Campa D; Canzian F; Castelao JE; Chang-Claude J; Chanock SJ; Cheng TD; Clarke CL; ; Colonna SV; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; Dennis J; Dörk T; Dossus L; Dunning AM; Dwek M; Eccles DM; Ekici AB; Eliassen AH; Eriksson M; Evans DG; Fasching PA; Flyger H; Fritschi L; Gago-Dominguez M; García-Sáenz JA; Giles GG; Grip M; Guénel P; Gündert M; Hahnen E; Haiman CA; Håkansson N; Hall P; Hamann U; Hart SN; Hartikainen JM; Hartmann A; He W; Hooning MJ; Hoppe R; Hopper JL; Howell A; Hunter DJ; ; ; Jager A; Jakubowska A; Janni W; John EM; Jung AY; Kaaks R; Keupers M; Kitahara CM; Koutros S; Kraft P; Kristensen VN; Kurian AW; Lacey JV; Lambrechts D; Le Marchand L; Lindblom A; Linet M; Luben RN; Lubiński J; Lush M; Mannermaa A; Manoochehri M; Margolin S; Martens JWM; Martinez ME; Mavroudis D; Michailidou K; Milne RL; Mulligan AM; Muranen TA; Nevanlinna H; Newman WG; Nielsen SF; Nordestgaard BG; Olshan AF; Olsson H; Orr N; Park-Simon TW; Patel AV; Peissel B; Peterlongo P; Plaseska-Karanfilska D; Prajzendanc K; Prentice R; Presneau N; Rack B; Rennert G; Rennert HS; Rhenius V; Romero A; Roylance R; Ruebner M; Saloustros E; Sawyer EJ; Schmutzler RK; Schneeweiss A; Scott C; Shah M; Smichkoska S; Southey MC; Stone J; Surowy H; Swerdlow AJ; Tamimi RM; Tapper WJ; Teras LR; Terry MB; Tollenaar RAEM; Tomlinson I; Troester MA; Truong T; Vachon CM; Wang Q; Hurson AN; Winqvist R; Wolk A; Ziogas A; Brauch H; García-Closas M; Pharoah PDP; Easton DF; Chenevix-Trench G; Schmidt MK
Breast Cancer Res; 2021 Aug; 23(1):86. PubMed ID: 34407845
[TBL] [Abstract] [Full Text] [Related]
6. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
Mirza MR; Benigno B; Dørum A; Mahner S; Bessette P; Barceló IB; Berton-Rigaud D; Ledermann JA; Rimel BJ; Herrstedt J; Lau S; du Bois A; Herráez AC; Kalbacher E; Buscema J; Lorusso D; Vergote I; Levy T; Wang P; de Jong FA; Gupta D; Matulonis UA
Gynecol Oncol; 2020 Nov; 159(2):442-448. PubMed ID: 32981695
[TBL] [Abstract] [Full Text] [Related]
7. Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment.
Havrilesky LJ; Lim S; Ehrisman JA; Lorenzo A; Alvarez Secord A; Yang JC; Johnson FR; Gonzalez JM; Reed SD
Gynecol Oncol; 2020 Mar; 156(3):561-567. PubMed ID: 31982178
[TBL] [Abstract] [Full Text] [Related]
8. A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study.
O'Cearbhaill RE; Deng W; Chen LM; Lucci JA; Behbakht K; Spirtos NM; Muller CY; Benigno BB; Powell MA; Berry E; Tewari KS; Hanjani P; Lankes HA; Aghajanian C; Sabbatini PJ
Gynecol Oncol; 2019 Dec; 155(3):393-399. PubMed ID: 31653510
[TBL] [Abstract] [Full Text] [Related]
9. Identification of Key Candidate Genes and Pathways for Relationship between ovarian cancer and Diabetes Mellitus Using Bioinformatical Analysis.
Sun Y; Xiaoyan H; Yun L; Chaoqun L; Jialing W; Liu Y; Yingqi Z; Peipei Y; Junjun P; Yuanming L
Asian Pac J Cancer Prev; 2019 Jan; 20(1):145-155. PubMed ID: 30678426
[TBL] [Abstract] [Full Text] [Related]
10. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
Moore KN; Mirza MR; Matulonis UA
Gynecol Oncol; 2018 Apr; 149(1):214-220. PubMed ID: 29397193
[TBL] [Abstract] [Full Text] [Related]
11. Therapy-related myelodysplasia and acute myeloid leukemia.
Bhatia S
Semin Oncol; 2013 Dec; 40(6):666-75. PubMed ID: 24331189
[TBL] [Abstract] [Full Text] [Related]
12. Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
Pautier P; Joly F; Kerbrat P; Bougnoux P; Fumoleau P; Petit T; Rixe O; Ringeisen F; Carrasco AT; Lhommé C
Gynecol Oncol; 2010 Feb; 116(2):157-62. PubMed ID: 20109725
[TBL] [Abstract] [Full Text] [Related]
13. [Secondary myelodysplasia and leukemia following carboplatin and paclitaxel-containing chemotherapy for ovarian cancer].
Abe A; Ikawa H; Muguruma H; Maeda Y
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1795-8. PubMed ID: 18931592
[TBL] [Abstract] [Full Text] [Related]
14. WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells.
Stauss HJ; Thomas S; Cesco-Gaspere M; Hart DP; Xue SA; Holler A; King J; Wright G; Perro M; Pospori C; Morris E
Blood Cells Mol Dis; 2008; 40(1):113-6. PubMed ID: 17855129
[TBL] [Abstract] [Full Text] [Related]
15. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors.
L'Espérance S; Popa I; Bachvarova M; Plante M; Patten N; Wu L; Têtu B; Bachvarov D
Int J Oncol; 2006 Jul; 29(1):5-24. PubMed ID: 16773180
[TBL] [Abstract] [Full Text] [Related]
16. Secondary leukemia after treatment with paclitaxel and carboplatin in a patient with recurrent ovarian cancer.
See HT; Thomas DA; Bueso-Ramos C; Kavanagh J
Int J Gynecol Cancer; 2006; 16 Suppl 1():236-40. PubMed ID: 16515597
[TBL] [Abstract] [Full Text] [Related]
17. [A novel molecular marker for thrombus formation and life prognosis--clinical usefulness of measurement of soluble fibrin monomer-fibrinogen complex (SF)].
Koga S
Rinsho Byori; 2004 Apr; 52(4):355-61. PubMed ID: 15164605
[TBL] [Abstract] [Full Text] [Related]
18. Decitabine: 2'-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716.
Drugs R D; 2003; 4(6):352-8. PubMed ID: 14584964
[TBL] [Abstract] [Full Text] [Related]
19. Interleukin-3 in hematology and oncology: current state of knowledge and future directions.
Mangi MH; Newland AC
Cytokines Cell Mol Ther; 1999 Jun; 5(2):87-95. PubMed ID: 10515681
[TBL] [Abstract] [Full Text] [Related]
20. The prognostic significance of peritoneal seeding and size of postsurgical residual in patients with stage III epithelial ovarian cancer treated with surgery, chemotherapy, and high-dose radiotherapy.
Kapp KS; Kapp DS; Poschauko J; Stücklschweiger GF; Hackl A; Pickel H; Petru E; Winter R
Gynecol Oncol; 1999 Sep; 74(3):400-7. PubMed ID: 10479500
[TBL] [Abstract] [Full Text] [Related]
[Next]
